CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer

In Hae Park, Joo Hyuk Sohn, Sung Bae Kim, Keun Seok Lee, Joo Seop Chung, Soo Hyeon Lee, Tae You Kim, Kyung Hae Jung, Eun Kyung Cho, Yang Soo Kim, Hong Suk Song, Jae Hong Seo, Hun Mo Ryoo, Sun Ah Lee, So Young Yoon, Chul Soo Kim, Yong Tai Kim, Si Young Kim, Mi Ryung Jin, Jungsil Ro

Cancer Research and Treatment. 2017;49(3):569-577. Published online 2016 September 12 DOI: https://doi.org/10.4143/crt.2016.289

Cancer Research and Treatment. 2017;49(3):569-577

Link1

Link2 Link3

48PEstimation of efficacy and safety of a Cremophor-free, polymeric micelle formulation of paclitaxel, in recurrent or metastatic breast cancer patients

S S Kang

Annals of Oncology. 2018;29(suppl_9):

Link1

Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002)

A.D. Santin, A.N. Fader

Gynecologic Oncology. 2018;149:12

Link1 Link2

E2100: A Phase III Trial of Paclitaxel Versus Paclitaxel/Bevacizumab for Metastatic Breast Cancer

Kathy D. Miller

Clinical Breast Cancer. 2003;3(6):421-422

Link1 Link2

Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer

David Miles, David Cameron, Magalie Hilton, Josep Garcia, Joyce O'Shaughnessy

European Journal of Cancer. 2018;90:153-155

Link1 Link2

1–37 Multicenter Randomized Phase III Trial of Epirubicin Plus Paclitaxel vs Epirubicin Followed by Paclitaxel in Metastatic Breast Cancer Patients: Focus on Cardiac Safety

A.D. Seidman

Breast Diseases: A Year Book Quarterly. 2005;16(1):71-72

Link1 Link2

Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic breast cancer

Zhong-Zhen GUAN, Qing Li LI, Fengyi FENG, Zefei JIANG, Zhenzhou SHEN, Shiying YU, Jifeng FEN, Jianjin HUANG, Zhiwen YAO, Paul BHAR

Asia-Pacific Journal of Clinical Oncology. 2009;5(3):165-174

Link1

An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021)

Shin-Wha Lee, Yong-Man Kim, Chi Heum Cho, Young Tae Kim, Seok Mo Kim, Soo Young Hur, Jae-Hoon Kim, Byoung-Gie Kim, Seung-Cheol Kim, Hee-Sug Ryu, Soon Beom Kang

Cancer Research and Treatment. 2018;50(1):195-203

Link1

Link2 Link3

Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1

Shin Nishio, Ryo Kitagawa, Taro Shibata, Hiroyuki Yoshikawa, Ikuo Konishi, Kimio Ushijima, Toshiharu Kamura

Cancer Chemotherapy and Pharmacology. 2016;78(4):785-790

Link1

Link2 Link3

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

S.W. Lam, S.M. de Groot, A.H. Honkoop, A. Jager, A.J. ten Tije, M.M.E.M. Bos, S.C. Linn, J. van den Bosch, J.R. Kroep, J.J. Braun, H. van Tinteren, E. Boven

European Journal of Cancer. 2014;50(18):3077-3088

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.